Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK6 | P43250 | 2/20 | 0.61 |
| ▸ | ADK | P55263 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14353019 | 0.81 | GRK6 (0.69) | GRK6ADKCA1CA2LMNA | |
| SCHEMBL14353020 | 0.81 | GRK6 (0.69) | GRK6ADKCA1CA2LMNA | |
| SCHEMBL14477729 | 0.81 | GRK6 (0.69) | GRK6ADKCA1CA2LMNA | |
| SCHEMBL12870524 | 0.79 | ADK (0.64) | GRK6ADKCA1CA2TSHR | |
| SCHEMBL4866861 | 0.79 | ADK (0.64) | GRK6ADKCA1CA2TSHR | |
| SCHEMBL12870506 | 0.77 | ADK (0.67) | GRK6ADKCA1CA2TSHR | |
| SCHEMBL4876463 | 0.77 | ADK (0.67) | GRK6ADKCA1CA2TSHR | |
| SCHEMBL16171111 | 0.76 | GRK6 (1.00) | GRK6ADKCA1CA2LMNA | |
| SCHEMBL4873338 | 0.76 | ADK (0.57) | GRK6ADKCA1CA2TSHR | |
| SCHEMBL12870449 | 0.75 | ADK (0.59) | GRK6ADKCA1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449570-B2 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-7291603-B2 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20060166926-A1 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
| US-20040067900-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166926-A1 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | NSUN2, UPF1, NSUN3 | GRK6 3946/4885ADK 523/4885MEN1 1877/4885 |
| US-20040067900-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | NSUN2, RNMT, NSUN3 | GRK6 3642/4885ADK 198/4885MEN1 1994/4885 |
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | NSUN2, RNMT, NSUN3 | GRK6 3642/4885ADK 198/4885MEN1 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.